ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

Patients with lung cancer who reported symptoms via Moovcare showed 1-year survival of 75%.

The highest retail prices for 23 different cancer drugs was found in the United States.

Adding temozolomide (Temodar) to chemoradiation reduced the risk of death by 33% in elderly glioblastoma patients.

Aggressive treatment approach shows promise in children with high risk brain cancer.

Choosing Wisely recommendations have not substantially changed the care received by patients in the last 30 days of life.

Women diagnosed with breast cancer who carry a BRCA mutation have up to a 50% lifetime risk of developing a second breast cancer.

Rovalpituzumab tesirine reduced tumor growth and even shrank tumors in some patients with small cell lung cancer.

Patients treated with chemotherapy and IMAB362 had a median overall survival of 16.7 months.

Bortezomib and dexamethasone slowed disease progression in patients with recurrent or refractory multiple myeloma.

Patients treated with atezolizumab had a longer median overall survival than patients treated with carboplatin-based regimens.

Postmenopausal women with early breast cancer showed a reduction in disease recurrence after 10 years of aromatase inhibitor therapy with letrozole.

Targeted treatment shows strongest efficacy in HER2 abnormalities.

Biosimilar trastuzumab antibody (MYL-1401O) comparable in efficacy and safety to targeted cancer drug in women with HER2-positive advanced breast cancer.

Patients receiving intraperitoneal and intravenous chemotherapy had progression-free survival of 59.3 months.

Capecitabine chemotherapy in combination with gemcitabine show median overall survival rate of 28 months.

Anaplastic glioma patients administered temozolomide after radiation, with or without concurrent temozolomide, saw a slower progression of the disease.

Precision medicine found to be associated with increased tumor reduction and progression-free survival.

Overall 3-year survival in patients with advanced melanoma taking pembrolizumab was 40%.

Family caregivers of patients with terminal cancers could benefit from early palliative care.

Patients with multiple myeloma receiving ASCT showed a 10% increase in tumor cell reduction.